US Stocks Move | Gilead Sciences drops 1.8% in after-hours trading as this year's product sales and profit guidance fall short of expectations

Glonghui, February 11｜Gilead Sciences (GILD.US) fell 1.8% in after-hours trading to $144.55. In terms of news, Gilead Sciences announced its fourth-quarter results for last year, with revenue increasing by 5% year-on-year to $7.9 billion, surpassing analysts’ expectations of $7.7 billion; adjusted earnings per share were $1.86, also exceeding the expected $1.81. During the period, sales of HIV-related products increased by 6% year-on-year to $5.8 billion, mainly driven by increased demand for HIV prevention and treatment; sales of Remdesivir fell 37% year-on-year to $212 million, mainly due to a decline in COVID-19-related hospitalization rates. Looking ahead to this year, Gilead Sciences expects product sales to be between $29.6 billion and $30 billion, and adjusted earnings per share to be between $8.45 and $8.85, while analysts’ expectations are $30.2 billion and $8.75, respectively. This guidance is affected by the company’s pricing agreement with the Trump administration, as well as uncertainties after the expiration of some government subsidies. (Glonghui)